CANTIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cantil, and when can generic versions of Cantil launch?
Cantil is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in CANTIL is mepenzolate bromide. There is one drug master file entry for this compound. Additional details are available on the mepenzolate bromide profile page.
Summary for CANTIL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 66 |
Patent Applications: | 1,724 |
DailyMed Link: | CANTIL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for CANTIL
US Patents and Regulatory Information for CANTIL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | CANTIL | mepenzolate bromide | SOLUTION;ORAL | 010679-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | CANTIL | mepenzolate bromide | TABLET;ORAL | 010679-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |